These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 29391054)

  • 1. suPAR is associated with risk of future acute surgery and post-operative mortality in acutely admitted medical patients.
    Meyer J; Alstrup M; Rasmussen LJH; Schultz M; Ladelund S; Haupt TH; Tingleff J; Iversen K; Eugen-Olsen J
    Scand J Trauma Resusc Emerg Med; 2018 Feb; 26(1):11. PubMed ID: 29391054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Soluble urokinase plasminogen activator receptor predicts mortality in exacerbated COPD.
    Godtfredsen NS; Jørgensen DV; Marsaa K; Ulrik CS; Andersen O; Eugen-Olsen J; Rasmussen LJH
    Respir Res; 2018 May; 19(1):97. PubMed ID: 29783959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Soluble urokinase plasminogen activator receptor (suPAR) in acute care: a strong marker of disease presence and severity, readmission and mortality. A retrospective cohort study.
    Rasmussen LJ; Ladelund S; Haupt TH; Ellekilde G; Poulsen JH; Iversen K; Eugen-Olsen J; Andersen O
    Emerg Med J; 2016 Nov; 33(11):769-775. PubMed ID: 27590986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma suPAR levels are associated with mortality, admission time, and Charlson Comorbidity Index in the acutely admitted medical patient: a prospective observational study.
    Haupt TH; Petersen J; Ellekilde G; Klausen HH; Thorball CW; Eugen-Olsen J; Andersen O
    Crit Care; 2012 Jul; 16(4):R130. PubMed ID: 22824423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of the prognostic biomarker suPAR in the emergency department improves risk stratification but has no effect on mortality: a cluster-randomized clinical trial (TRIAGE III).
    Schultz M; Rasmussen LJH; Andersen MH; Stefansson JS; Falkentoft AC; Alstrup M; Sandø A; Holle SLK; Meyer J; Törnkvist PBS; Høi-Hansen T; Kjøller E; Jensen BN; Lind M; Ravn L; Kallemose T; Lange T; Køber L; Rasmussen LS; Eugen-Olsen J; Iversen KK
    Scand J Trauma Resusc Emerg Med; 2018 Aug; 26(1):69. PubMed ID: 30153859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Soluble Urokinase Plasminogen Activator Receptor (suPAR) as an Added Predictor to Existing Preoperative Risk Assessments.
    Alstrup M; Meyer J; Schultz M; Rasmussen LJH; Rasmussen LS; Køber L; Forberg JL; Eugen-Olsen J; Iversen K
    World J Surg; 2019 Mar; 43(3):780-790. PubMed ID: 30390135
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combining National Early Warning Score With Soluble Urokinase Plasminogen Activator Receptor (suPAR) Improves Risk Prediction in Acute Medical Patients: A Registry-Based Cohort Study.
    Rasmussen LJH; Ladelund S; Haupt TH; Ellekilde GE; Eugen-Olsen J; Andersen O
    Crit Care Med; 2018 Dec; 46(12):1961-1968. PubMed ID: 30247244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The biomarkers suPAR and blood eosinophils are associated with hospital readmissions and mortality in asthma - a retrospective cohort study.
    Håkansson KEJ; Rasmussen LJH; Godtfredsen NS; Tupper OD; Eugen-Olsen J; Kallemose T; Andersen O; Ulrik CS
    Respir Res; 2019 Nov; 20(1):258. PubMed ID: 31730462
    [TBL] [Abstract][Full Text] [Related]  

  • 9. suPAR as a biomarker for risk of readmission and mortality in the acute medical setting.
    Nayak RK; Allingstrup M; Phanareth K; Kofoed-Enevoldsen A
    Dan Med J; 2015 Oct; 62(10):A5146. PubMed ID: 26441392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High suPAR and Low Blood Eosinophil Count are Risk Factors for Hospital Readmission and Mortality in Patients with COPD.
    Håkansson KEJ; Ulrik CS; Godtfredsen NS; Kallemose T; Andersen O; Eugen-Olsen J; Marsaa K; Rasmussen LJH
    Int J Chron Obstruct Pulmon Dis; 2020; 15():733-743. PubMed ID: 32308381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Using soluble urokinase plasminogen activator receptor to stratify patients for medication review in the emergency department.
    Bengaard AK; Iversen E; Kallemose T; Juul-Larsen HG; Rasmussen LJH; Dalhoff KP; Andersen O; Eugen-Olsen J; Houlind MB
    Br J Clin Pharmacol; 2022 Feb; 88(4):1679-1690. PubMed ID: 34242432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Introduction of a prognostic biomarker to strengthen risk stratification of acutely admitted patients: rationale and design of the TRIAGE III cluster randomized interventional trial.
    Sandø A; Schultz M; Eugen-Olsen J; Rasmussen LS; Køber L; Kjøller E; Jensen BN; Ravn L; Lange T; Iversen K
    Scand J Trauma Resusc Emerg Med; 2016 Aug; 24():100. PubMed ID: 27491822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Soluble urokinase plasminogen activator receptor is linearly associated with dietary quality and predicts mortality.
    Törnkvist PBS; Haupt TH; Rasmussen LJH; Ladelund S; Toft U; Pisinger C; Eugen-Olsen J
    Br J Nutr; 2019 Mar; 121(6):699-708. PubMed ID: 30626457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma level of soluble urokinase plasminogen activator receptor (suPAR) predicts long-term mortality after first acute alcohol-induced pancreatitis.
    Aronen A; Aittoniemi J; Huttunen R; Nikkola A; Nikkola J; Limnell O; Nordback I; Sand J; Laukkarinen J
    Eur J Intern Med; 2019 Jun; 64():72-75. PubMed ID: 31060962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Soluble Urokinase-Type Plasminogen Activator Receptor Improves Risk Prediction in Patients With Chronic Heart Failure.
    Koller L; Stojkovic S; Richter B; Sulzgruber P; Potolidis C; Liebhart F; Mörtl D; Berger R; Goliasch G; Wojta J; Hülsmann M; Niessner A
    JACC Heart Fail; 2017 Apr; 5(4):268-277. PubMed ID: 28359415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Soluble urokinase plasminogen activator receptor for risk prediction in patients admitted with acute chest pain.
    Lyngbæk S; Andersson C; Marott JL; Møller DV; Christiansen M; Iversen KK; Clemmensen P; Eugen-Olsen J; Hansen PR; Jeppesen JL
    Clin Chem; 2013 Nov; 59(11):1621-9. PubMed ID: 23842203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of suPAR and hs-CRP on cardiovascular disease.
    Diederichsen MZ; Diederichsen SZ; Mickley H; Steffensen FH; Lambrechtsen J; Sand NPR; Christensen KL; Olsen MH; Diederichsen A; Grønhøj MH
    Atherosclerosis; 2018 Apr; 271():245-251. PubMed ID: 29402404
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population.
    Eugen-Olsen J; Andersen O; Linneberg A; Ladelund S; Hansen TW; Langkilde A; Petersen J; Pielak T; Møller LN; Jeppesen J; Lyngbaek S; Fenger M; Olsen MH; Hildebrandt PR; Borch-Johnsen K; Jørgensen T; Haugaard SB
    J Intern Med; 2010 Sep; 268(3):296-308. PubMed ID: 20561148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic Value of Soluble Urokinase-Type Plasminogen Activator Receptor and High-Sensitivity C-Reactive Protein on Postoperative Mortality in Patients Undergoing Elective On-Pump Cardiac Surgery.
    Rasmussen SR; Nielsen RV; Eriksson F; Dons M; Vedel AG; Buggeskov KB; Møgelvang R; Ostrowski SR; Ravn HB
    J Cardiothorac Vasc Anesth; 2021 Aug; 35(8):2415-2423. PubMed ID: 33243671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating soluble urokinase plasminogen activator receptor is stably elevated during the first week of treatment in the intensive care unit and predicts mortality in critically ill patients.
    Koch A; Voigt S; Kruschinski C; Sanson E; Dückers H; Horn A; Yagmur E; Zimmermann H; Trautwein C; Tacke F
    Crit Care; 2011; 15(1):R63. PubMed ID: 21324198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.